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ABSTRACT

Leukemias are the most common form of childhood cancer making up 30% of
total pediatric oncological cases, and Acute Lymphoblastic Leukemia (ALL) makes up a
significant portion (12%) of the total pediatric cancer diagnoses. In 2017, the FDA
approved a successful immunotherapy called CAR-T therapy for the treatment of
pediatric B-cell ALL. This therapy includes a CAR (chimeric antigen receptor) that is
loaded into the T-cell and expressed. Currently, the loading of the CAR utilizes viral
transduction, but consistency issues lead to adverse symptoms in the patients. Better
methods of transduction/transfection are being studied in order to improve these
consistency concerns. In this thesis, the efficiency of sonoporation as a non-viral method
of transfection was assessed. Fluorescein was loaded as a fluorescent model molecule for
beginning understanding of the sonoporation efficiency. It was found that by using
sonoporation over electroporation for the uptake of fluorescein, the efficiency is
improved by 34%. When sonoporation was used for the transfection of GFP plasmid, the
same increase was not proven. This leads to the conclusion that without further
optimization, sonoporation is successful at loading small molecule such as fluorescein but
not those as large as plasmids. With optimization, sonoporation could eventually be used
as a non-viral method to transfect T-cells with CARs for CAR-T therapy and the
treatment of ALL in both children and adults.
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I. INTRODUCTION

Objective

The objective of this thesis is to assess the efficiency of sonoporation to transfect
primary T-cells with plasmid for its potential use as a non-viral method of transfection for
CAR-T therapy for patients battling Acute Lymphoblastic Leukemia.

Overview of Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia (ALL) is a malignant bone marrow disease where
early lymphoid precursors proliferate and replace normal cells. It can arise from several
genetic mutations in either B- or T-progenitor cells that result in the overproduction of
these immune cells. If mistreated or left untreated, the genetic mutation can lead to a lethal
buildup of leukemic cells in the body [1, 2].
Leukemias are the most common form of childhood cancer making up 30% of total
pediatric oncological cases, and ALL makes up a significant portion (12%) of the total
pediatric cancer diagnoses. Its population distribution is bimodal, however, with one
population centered around age 4-5 and another age 50+. Children 5 years and younger are
at the highest risk of developing this disease and this thesis focuses mainly on pediatric
ALL [3]. Fortunately, the patient response to current treatments has allowed for an 98%
remission rate in children and an 85% five-year survival rate where patients are considered
cancer-free.
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The steps of hemopoiesis begins with a blood stem cell, referred to as a hemopoietic
stem cell. This stem cell differentiates into either a myeloid stem cell or a lymphoid stem
cell. On the myeloid side, the stem cell further differentiates into red blood cells, platelets,
or a myeloblast. The differentiation then terminates after myeloblasts develop into
granulocytes (eosinophils, basophils, or neutrophils). Going back to the lymphoid stem cell
line, these stem cells differentiate into lymphoblasts first, followed by B lymphocytes, T
lymphocytes, or Natural Killer (NK) cells. The three granulocytes in addition to the
lymphoblasts make up what is considered white blood cells which are vital cells in the
immune system and this is where the problems originate in ALL [4]. Many subclassifications of ALL exist, however only three differ therapeutically: B-cell precursor, TCell precursor, and mature B-Cell [1, 2]. Knowing the cell lineage is important as proper
diagnosis is crucial for an oncologist to determine an effective treatment regimen.

Pathobiology
Although it is rare for an adult to develop ALL, B-cell precursor ALL is the most
common type of the adult form of the disease [1, 2]. The TEL-AML1 fusion gene is the
distinguishing mutation in B-cell precursor ALL. This gene is generated by the

Figure 1A (left): A schematic representation of the translocation process during the TEL-AML1 fusion. This
translocation occurs between chromosome 12 and 21 [5].
Figure 1B (right): Microscopic representation of the TEL-AML1 gene fusion. Red = AML1 gene, Green = TEL gene,
Blue = CD10 (leukemic antibody), Yellow = colocalization of the genes [5].
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t(12;21)(p13;q22) chromosomal translocation (Figure 1) [5]. The TEL gene is significant
in the natural development of hematopoietic cells during hemopoiesis. The AML1 gene is
significant in embryonic hemopoiesis. The fusion of these two genes creates problems in
the development of B-lineage lymphocytes [5].
Another type of ALL is T-cell precursor which can be defined in 50% of its cases
by mutations involving the NOTCH1 gene. This gene mutation is generated by the
t(7;9)(q34;q34.3) translocation. NOTCH regulates normal T-cell development through the
creation of a transmembrane receptor. The mutation causes an overexpression of an active
form of NOTCH that inhibits cell differentiation [6].
In 20-30% of ALL cases occurs what is called the Philadelphia chromosome, or the
t(9;22) chromosomal translocation, meaning a fragment of chromosome 9 switches places
with a fragment of chromosome 22. In these cases, the B-cell antigen receptor (BCR)
signaling protein binds to the Abelson (ABL) non-receptor tyrosine kinase. This takes place
on chromosome 22 where the broken off piece of chromosome 9 has attached. This results
in tyrosine kinase activity overdrive and the interaction of this fused protein with other
elements such as the signaling protein for RAS (renin-angiotensin system). Fortunately, it
has been discovered that Imatinib Mesylate, a chemotherapeutic drug, selectively targets
this gene fusion and has proven effective in Philadelphia chromosome-specific cases.
Imatinib mesylate works by inhibiting tyrosine kinase activity by binding to an intracellular
pocket in the tyrosine kinase. This binding inhibits ATP binding and prevents
phosphorylation that allows for cell growth [1, 2, 7, 8].
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Symptoms
The symptom list of ALL is broad, however it can be broken down into smaller
categories to help discuss the multitude of symptoms. Symptoms caused by low numbers
of blood cells in the patient can include fatigue, weakness, dizziness or lightheadedness,
shortness of breath, pale skin, infections that are difficult to get rid of, bruising, and
abnormal bleeding such as reoccurring nose bleeds or bleeding gums. The overcrowding
of leukemic cells in the bone marrow make it difficult for the marrow to produce sufficient
amounts of other blood cell types, such as red blood cells. Red blood cells are responsible
for the delivery of oxygen to tissues in the body; therefore, a lack of red blood cells can
cause anemia-like symptoms such as fatigue, weakness, dizziness and shortness of breath
[4, 9, 10].
General symptoms that are harder to link to ALL include weight loss, fever, night
sweats, and loss of appetite. These symptoms are considered non-specific and are most
likely caused by something other than leukemia in the patient. However, these symptoms
are indicative of the immune system working to rid the body of something unnatural.
Abnormal or excess T-cells in the body stimulates the immune system, which is why these
occurrences can be considered non-specific symptoms of ALL.
Symptoms caused by a buildup of cells include swelling in the abdomen, enlarged
lymph nodes, bone or joint pain, and an enlarged thymus. Leukemia cells can build up in
the liver or spleen, causing swelling and fullness in the abdomen of the patient. Feeling full
after ingesting a small amount of food can indicate this swelling due to decreased room for
expansion by the stomach. The pressure of the liver and spleen on other abdominal organs
would also cause this sensation. Even though these organs are covered by the lower ribs, a
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swollen liver and spleen are detectable by a palpation exam. If ALL spreads to the lymph
nodes, the buildup of excess cells can cause swelling. This may be more obvious in the
neck, groin, or underarm areas, however swelling of lymph nodes in the chest and abdomen
can also occur. CT or MRI scans would be necessary to determine swelling in these areas.
If there is a buildup of cells around bones or inside the joint, pain can also occur in these
areas [4, 9, 10].

Diagnosis
If symptoms discussed above occur in a patient, an oncologist will initiate what will
become a lengthy diagnosis process. Blood tests, bone marrow biopsy and aspiration,
lumbar puncture, immunophenotyping/genotyping all might be necessary in order to
diagnose ALL [2]. During a blood smear, the oncologist will look for increased levels of
lymphoblasts and lymphocytes which is proof of the overproduction of immune cells that

A

B

C

D

Figure 2: Blood smears (images A and B) and bone
marrow aspiration smears (images C and D) are a normal
part of the diagnosis process for ALL. In diseased states,
an increase in lymphoblasts and lymphocytes will be
present in the blood and bone marrow (images B and D).
These immune cells are dyed purple in the above
microscopy [11].

5

defines ALL [11] (Figure 2). A CBC (complete blood count) and differential blood count
will also be conducted to evaluate the ratio of white blood cells in the blood. Elevated
levels of lymphoblasts will also be measured in the bone marrow through bone marrow
aspiration. A large needle will be inserted into either the hip bone or breast bone of the
patient and bone marrow will be removed for evaluation. This process normally includes a
bone/bone marrow biopsy simultaneous to the aspiration. In some cases, the leukemia will
spread to the central nervous system and a lumbar puncture is required. Furthermore,
immunophenotyping and genotyping is conducted to get a thorough diagnosis. Flow
cytometry, RT-PCR, and fluorescent in-situ hybridization (FISH) are all utilized for this
process. Flow cytometry can detect the presence of leukemic antibodies on the T-cells
while RT-PCR and FISH can detect changes in the DNA and genetic makeup [2].

Treatment (leading up to CAR-T)
As discussed previously, the current treatments for ALL tend to be successful with
a child remission rate of 98% and child five-year survival rate of 85% [1-3]. Current
treatment methods include chemotherapy in three stages based on the patients’ risk
assessment and an allogeneic hemopoietic stem cell transplantation if necessary. In patients
that express the Philadelphia Chromosome, tyrosine kinase inhibitors are instilled in
addition to the chemotherapeutics.
The first stage of chemotherapy is called the remission-induction phase. Its goal is
to eradicate 99% of the leukemic cells present in these patients and reinstate normal
hemopoiesis. This stage commonly includes a three-drug cocktail consisting of a
glucocorticoid (prednisone or dexamethasone), vincristine, and asparaginase or
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anthracycline. This three-drug combination is usually sufficient for patients that are
considered standard-risk. In high- to very high-risk patients, asparagine and anthracycline
can both be administered, resulting in a four or more drug treatment [1, 2].
Following the remission-induction phase is the consolidation, or intensification,
treatment phase. Once the patient shows signs of normal hemopoiesis the intensification
process is meant to eliminate the drug-resistant leukemic cells. This elimination reduces
the risk of relapse. Although currently there is not a consensus on the best treatment
regimen, oncologists will often use high doses of methotrexate, mercaptopurine, frequent
vincristine and corticosteroid dosages and high-dose asparaginase for 20-30 weeks.
Reinduction treatment of the same drugs used during the induction-remission stages for the
patient are often used during the intensification stages as well to further enhance treatment
outcome. One study conducted in Philadelphia concluded that double reinduction treatment
was vital to patient success while additional administration of vincristine and prednisone
after one reinduction round was not useful [1, 2, 12].
Allogenic hemopoiesis stem-cell transplantation is conducted in patients when
necessary. It is the most rigorous form of treatment for ALL and only utilized when
necessary. The benefit in patients with high-risk ALL, Philadelphia Chromosome-positive
patients, and adults with the t(4;11) translocation gene mutation has been proven, however
the necessity in infant regimens is controversial. Finding a stem-cell match for patients can
be difficult, as 7/10 patients do not have a human leukocyte antigen (HLA) match in their
family and must rely on outside donors. Finding matches has become more common since
the 1990s with the establishment of bone marrow registries such as Be the Match [13].
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Continuation treatment takes place in most patients following their previous
chemotherapy and possible stem cell transplantations. Although 2/3 of patients can be
successfully treated within the first 12 months of treatment, often oncologists will continue
their treatment for 2-2.5 years to decrease the chance of relapse. This continuation
treatment includes daily mercaptopurine and mexotrexate, often in pill or liquid form to be
taken orally. Side effects of these medications include liver damage, high blood pressure,
hair loss, and swelling of the body [14]. As with most treatment regimens, there are areas
that still need to be improved. As our medical world advances, individualized treatments
that utilize immunoengineering has become more common [1, 2].

CAR-T Therapy, an Engineering Solution
The earliest attempt at engineering T-cells for the treatment of ALL included
expression of cloned T-cell receptors (TCR). These receptors can recognize intracellular
and extracellular antigens in the context of the major histocompatibility complex (MHC)
which is the all-encompassing term used for the surface proteins essential for the immune
system to recognize and destroy foreign particles. The problem with this method is that
many tumors downregulate MHC expression, making the detection by TCRs difficult. In
2017, the FDA approved a successful immunotherapy called CAR-T therapy for the
treatment of pediatric B-cell ALL. In this therapy, an artificial receptor called a CAR
(chimeric antigen receptor) is loaded into a patient’s T-cells [15]. The expression of the
CAR allows for detection of leukemic cells that express specific CD (cluster of
differentiation) markers. The idea of CAR loading was first described in 1990 as a way to
add specificity to tumor targeting methods. It was not until 2010, however, that the first
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clinical trial took place [16, 17]. The CAR method of T-cell engineering is MHCindependent and has proven more successful than the TCR attempt [18].
The ideal antigen to target on cancer cells would be on the surface and a result of
gene translocation or mutations occurring in these cells. This type of antigen is difficult to
find, so the next best thing is CD19, the most common and successfully targeted antigen
[19]. This is the antigen targeted in the FDA-approved treatment, tisagenlecleucel [8].
CD19 is expressed on the surface of B-cells and have a single cell lineage. Its function is
replaceable, making it an ideal target for CAR-T treatment. It is not only expressed in ALL,
but also chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphomas, meaning
CAR-T targeting CD19 could treat multiple cancers types [16, 17].
One of the areas for improvement in current CAR-T therapy is the inconsistency of
CAR-loading. Viral transduction causes random insertion into the genome. Variability in
insertion can cause inconsistent levels of receptor expression. This is thought to be the
cause for some adverse symptoms including cytokine release syndrome and neurotoxicity,
in addition to high fever, delirium, seizures, and even coma in rare yet severe cases [20,
21]. One trigger of cytokine release syndrome is tumor lysis syndrome. If T-cells are
overactive, too many cancer cells are killed at once. This causes an increased release of
potassium, phosphorus, and nucleic acids from the cancer cells which can cause
hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia, and their related
side effects [22]. In some retroviral reports, this random insertion approach has resulted in
the creation of an oncogene [16, 17]. Guided gene editing, such as CRISPR-Cas9, or a
change in the transfection/transduction method could potentially add consistency to the
CAR expression.
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Transfection Overview
Artificial gene delivery into cells, a technique referred to as transfection, has
become a large focus for the treatment of diseases. Cancer, heart failure, and hemophilia
are just a few of the areas where transfection has proven significant for the discovery of
new treatments. For many years viral transfection, a technique referred to as transduction,
has been the primary technique for gene delivery. As problems with this method arose
(such as safety and limitations in targeting and plasmid size) the search for non-viral
methods began to take place. It was soon understood that non-viral methods have similar,
if not better, success with penetrating the cell membrane. The areas in which improvements
still exist for non-viral methods are the transfection efficiency, unwanted degradation of
DNA, and limitations with nucleus translocation [23]. In this section we will explore the
different forms of transfection along with the benefits and drawbacks of each (Table 1).

Transfection
Technique

Pros

Cons

•

•

•
•
Viral Transfection
(Transduction)

Inherent ability to transfect
DNA
High transfection efficiency
Ability to translocate to the
nucleus

•
•
•
•

Electroporation

•
•
•
•

Pores stay open for minutes
Low toxicity
Low immunogenicity
Ease of manufacturing

•
•
•
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Gene randomly
inserted
Safety – insertion
mutagenesis
Manufacturing
difficulties
Limitations of
plasmid size
Limitations of
targeting
Microscale setups –
throughput
Macroscale setups –
transfection
efficiency
Passive process

•

•
•
Cationic Transfection
Reagents

•
•
•
•
•

Sonoporation

•
•
•

•
•
•

Low toxicity
Low immunogenicity
Ease of manufacturing
Active process –
microjetting/microstreaming
Possible at low
temperatures (4C),
increasing cell viability
Spatiotemporal control
Noninvasive
Delivers to cytoplasm (in
comparison to endosomal
entrapment by other lipid
based/nanoparticle
endocytosis methods)
Low toxicity
Low immunogenicity
Ease of manufacturing

•

•
•
•

Optimization for
different cell types
(voltage, capacitance,
temperature, etc.)
Lower transfection
efficiency than viral
methods
Pores stay open for
minutes
Lower transfection
efficiency than viral
methods
Microscale setups –
throughput
Lower transfection
efficiency than viral
method
Optimization
necessary (bubble
dose, flow rate,
ultrasound settings,
etc.)

Table 1: A summary of the pros and cons of transfection methods.

Viral Transduction
Transduction is the primary method used in gene therapy and CAR-T specifically
(i.e. using viruses (viral vectors) to deliver DNA to a cell for gene insertion/modification.)
The virus that is used as a vehicle for insertion does not contain enough of its DNA to
replicate and is termed “replication-deficient.” Despite the fact that these viruses cannot
replicate, transduction is not free of problems as safety is a major concern with viral
transduction. Controlling the final destination of the sequence transferred by the virus is
still difficult and can lead to insertional mutagenesis [23, 24]. Until sufficient assays arise
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to predict these mutations, this problem surrounding random insertion will continue to
exist. As more clinical trials are approved using these techniques, appropriate assays will
become more necessary [24].

Electroporation
In electrical terms, a cell membrane can be compared to a capacitor - storing
electrical energy but not passing current without the assistance of ion channels.
Considering this concept, one method of non-viral transfection is by administering
electrical pulses to the membrane which allows for a temporary membrane breakdown; a
process termed electroporation. Pores that can last a couple minutes are formed in the cell
membrane which allows molecules such as nucleic acids to pass through via diffusion and
potentially reach the nucleus [25, 26]. This technique has proven successful for both stable
and transient transfection on many different cell types. However, optimizing the pulse
duration, voltage intensity, and electroporation buffer being used is crucial for each cell
type. Both high voltage with low capacitance (short pulse duration) and low voltage with
high capacitance (long pulse duration) have transfected cell lines but the optimal
parameters are different for each cell type. For example, primary cells are more sensitive
and experience toxicity under high voltage, so short pulse durations would not be safe for
the transfection of these cells. The optimal temperature at which the cells are electroporated
can also vary, as keeping the cells on ice can improve viability but some long pulse duration
treatments are most effective at room temperature. Commercial electroporation products
have been made available, with programmable pulse duration and voltage to help ease the
optimization process of different cell lines. This helped make electroporation a popular
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non-viral technique for loading desired molecules into cells [26]. Challenges surrounding
this technique remain - specifically how quickly large amounts of cells can be processed.
In macro-scale setups, both transfection efficiency and cell viability may suffer. Meanwhile
in micro-scale experimental setups, throughput and processing time for large cell amounts
becomes a problem. When transfection is necessary, large amounts of cells are needed for
the treatment to work effectively [27].

Cationic Transfection Reagents
Another form of transfection involves cationic liposomes, polymers, proteins or
peptides to permeate the cell membrane. Companies have released commercialized
products to aid this technique, such as Lipofectamine by Thermo Fisher Scientific and
Fugene by Promega. The cationic vehicles loaded with plasmid bind to surface proteins
and activate signaling pathways that cue for endocytosis [23]. This form of non-viral
transfection has not been shown to have higher transfection efficiency than viral methods,
however it is less toxic and induces fewer immune responses.

Sonoporation/Ultrasound-mediated Delivery
The process of exposing tissue to ultrasound waves to increase the permeability of
the cell membrane is another form of non-viral transfection called sonoporation [28]. This
process can be improved by the addition of lipid-shelled, gas-cored microbubbles. When
the exposure to ultrasound pulses causes the microbubbles to oscillate, at sufficiently high
amplitudes they can collapse (inertial cavitation) and create temporary pores in the cell
membrane in addition to a microjet that can force the nearby liquid into the cells [29, 30].
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In this way, sonoporation can be both an active and passive process in comparison to
electroporation which relies more so on passive diffusion [29]. These transient pores can
reseal as quickly as a minute after their creation, allowing the cell to swiftly recover and
return to normal function. This process allows for spatiotemporal control, allowing for a
vast array of possible therapeutic uses, including mammalian cell transfection [31].

Ultrasonic Flow System
One proposed method to add consistency to the loading of a CAR is through an
ultrasonic flow system that utilizes sonoporation as a method of transfection. The
sonoporation allows for a mechanical process to load the T-cells with the CAR (Figure 3)

T

Ultrasound

Figure 3: A combination flow/sonoporation system could
be used as a transfection method for loading CARs into Tcells. This process is non-viral and shows potential
consistency benefits.

[28]. A device to test this method was created in Dr. Jonathan Kopechek’s laboratory at
the University of Louisville prior to the beginning of this thesis. Previous to the fabrication
of the device, this sonoporation process was conducted in a bulk setup. A clinical
ultrasound probe was aimed at a conical tube in a water tank (for coupling purposes) and
the cells were treated with ultrasound waves. This set up resulted in inconsistent ultrasound
exposure and shielding of a portion of the cells caused by the microbubbles closer to the
ultrasound source attenuating ultrasound waves before reaching cells further away from
the source. To fix this issue and add consistency to the treatment, a microfluidics device
14

Arduino
microcontroller
A

Single-element PZT
transducers

Tubing to/from
syringe pumps

B

PDMS-based microfluidic
device

On/Off push
button

Figure 4: (A) Microfluidics device design that is in ultrasonic flow system. The channel width is 500
microns. (B) Ultrasonic flow device created in Dr. Jonathan Kopechek's laboratory. The device includes
an integrated PZT transducer that applies ultrasound directly to the cells flowing through the
microfluidics setup within the device.

was implemented into the sonoporation process. After testing a multitude of designs, a
concentric circle was decided upon for the microfluidic channels (Figure 4-5). This design
prolongs the exposure the cells receive to the ultrasound waves. To avoid using a clinical
probe to treat the cells, a PZT ultrasound transducer was attached directly to the
microfluidics device (Figure 5). The ultrasound transducer is microcontroller-driven,
which has been set up next to the microfluidics device. The Arduino, circuit board, and
microfluidics device were then encased in a 3D-printed container that included holes for
the tubing, power cords, and power button. When using this device to process, the cells are
pumped using a syringe pump (not shown in Figure 5) into the tubing. The cells,
microbubbles, and desired loading molecule flow through the entrance tubing (Figure 5),
into the microfluidics device where they are exposed to the ultrasound waves, and out the
exit tubing to be collected in a vial for post-treatment assessment.
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Figure 5: Microscopy image of red blood cells flowing through a
microfluidics device. The arrows point to the stream of red blood
cells.

This device allows for versatility as the microfluidics design can be adjusted along
with the ultrasound and flow parameters. With some additional effort, the device can be
optimized to load a multitude of cell types with many different small molecules [28]. To
date, cancer cells, red blood cells, and immune cells have been processed in this specific
device. With effort to optimize the necessary parameters, this ultrasonic flow system could
be a non-viral alternative for transfection of T-cells for CAR-T therapy.

CAR-T Shortcomings and Room for Improvement
The current pipeline for CAR-T treatment is lengthy and has opportunity for
improvement. As is, blood collection from the patient takes place which includes all blood
cell types. T-cell isolation and activation occurs in order to separate out the T-cells for
further engineering. This process includes the introduction of magnetic beads with CD3
and CD28 antibodies onto the T-cells. The now-isolated cells are then engineered through
viral transduction so that they will express the sought-after CAR. The T-cells must then be
multiplied ex-vivo for 10-14 days to reach the therapeutically necessary number of cells.
Often 109 to 1010 T-cells are required for the transfusion to work. After expansion, the
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magnetic beads are removed from the cell solution and prepared for transfusion. To
precondition the patient for receiving the treatment, they must receive conditional
chemotherapy drugs shortly before transfusion [32].
Most medical centers do not have the GMP-compliant facilities to conduct this
process. Therefore, cells needing to be processed must be stored through refrigeration or
freezing and shipped to processing facilities, processed, stored again, and shipped back to
the hospital. This lengthy process can cause unwanted phenotypical changes in the T-cells
and can take several weeks for the patient to receive their treatment [33, 34].
Several severe challenges also limit the safety and availability of this treatment in
patients. Some adverse symptoms seen include cytokine release syndrome and
neurotoxicity [20, 21]. This random retroviral approach has resulted in the creation of an
oncogene in some studies [16, 17]. It is thought that these symptoms are a result of the
variability in CAR expression. Currently, lentiviral or retroviral vectors are primarily used
for CAR expression. Although this creates a permanent modification to the gene, this
approach has its drawbacks as the CAR-expressing gene is randomly inserted into the
genome [20, 21]. A more consistent and direct method of loading the CAR into T-cells
would be beneficial to patient success. Therefore, we hypothesized that the use of
microfluidic sonoporation will increase the efficiency and consistency of T-cell
transfection.
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II. PROCEDURE

Fabrication/Setup of Device
A 3-inch silicon wafer coated with SU-8 was produced in a clean room by a
standard photolithography process to generate the master design. PDMS (SylGard 184
Silicone Elastomer Kit (Dow Corning - 184 SIL ELAST KIT 0.5KG) was mixed and
poured over the wafer in a petri dish. The PDMS was baked in a laboratory oven to cure,
cut to size, and hole punched. The PDMS devices were then plasma-bonded on glass
slides (MilliporeSigma, Burlington, MA, USA) and tubing was added. The PZT transducer
(StemInc, Millbrae, CA, USA) was attached directly to the bottom of the microfluidics device
and positioned in the 3D printed case. An Arduino Uno microcontroller (Arduino, Somerville,
MA, USA) was programmed and wired in the case to drive the transducer. The Arduino was
plugged in and a syringe with cell solution was connected to the input side of the tubing and
controlled by air pressure from an empty 60 mL syringe using an Aladdin syringe pump (Aladdin
Single-Syringe infusion Pump, World Precision Instruments, LLC, Sarasota, FL, USA). The
output was connected into a collection vial and the device was ready for cell processing.

A549 Cell Culture and Harvesting
A549 cells were cultured in complete DMEM media (10% fetal bovine serum, 1%
penicillin/streptomycin) (VWR, Radnor, PA, USA) at 37 oC and 5% CO2. Before harvesting, the
cells were washed once with PBS. Trypsin (0.25%) EDTA (VWR, Radnor, PA, USA) was added
to release the adherent cells and incubated for 5 minutes. The solution was neutralized with
complete media, collected in a conical tube, and centrifuged at 1500g for 5 minutes at 4 oC. The
cells were resuspended at a concentration appropriate for the experiment.
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Primary T-Cell Isolation
The peripheral blood mononuclear cell (PBMC) samples were kept at -150 oC for storage.
After retrieval, the frozen vials were quickly thawed in a water bath at 37 oC. The cells were
diluted 1:10 in PBS, transferred to a 15-mL conical, and centrifuged at 580g at 4 oC for 11
minutes. The supernatant was aspirated, and 13 mL of autoMACS running buffer was added
(MACS Miltenyi Biotec, Bergisch Gladbach, Germany). The cells were counted using an
automated cell counter. The cells were centrifuged again, and the supernatant was aspirated.
While keeping the solutions cold, the cells were resuspended in 40 μL of running buffer per 10
million cells. 10 μL of Pan T-Cell Biotin Antibody Cocktail was added per 10 million cells
(MACS Miltenyi Biotec, Bergisch Gladbach, Germany) for isolation of T-cells. The cells were
mixed well and incubated at 4 oC for 5 minutes per 10 million cells. 30 μL of buffer and 20 μL of
Pan T-Cell MicroBead Cocktail was added per 10 million cells (MACS Miltenyi Biotec, Bergisch
Gladbach, Germany). The cells and beads were mixed well and incubated for an additional 15
minutes at 4 oC. Rinsing buffer was added to make the total volume 500 μL. The cells were
separated using an autoMACS Pro Separator (MACS Miltenyi Biotec, Bergisch Gladbach,
Germany) using the “depletes separation” setting. The cells were counted again using an
automated cell counter. The cells were diluted in 10 mL PBS and centrifuged. The supernatant
was aspirated, and the cells were resuspended in 1 mL PBS and counted again. The cells were
then aliquoted into the appropriate amount of microcentrifuge tubes, the plasmid or fluorescein
was added, and experiments were conducted.

Microbubble synthesis
Microbubbles were synthesized as previously described in Kopechek, et al., 2015 for
studies involving ultrasound treatment [30]. The microbubbles were composed of a gas
perfluorocarbon core surrounded by a lipid shell. Cationic microbubble lipid solution was
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composed of 100:43:1:4.5 molar ratio (DSPC:DSEPC:DSPG:PEG-40). Neutral microbubble lipid
solution was composed of 96:4 molar ratio of DPPC:DSPE-PEG2000. All phospholipids were
obtained from Avanti Polar Lipids (Alabaster, AL, USA) except for polyethylene glycol-40
stearate (Sigma-Aldrich, St. Louis, MO, USA). Lipids were dissolved in chloroform and the
solvent was evaporated under argon. The dry lipid film was rehydrated in phosphate buffered
saline (PBS) to a concentration of 10 mg/mL and sonicated with a probe sonicator to disperse the
lipids.
To produce microbubbles, the prepared lipid solution was diluted 4x in PBS in a clear
11mm glass crimp vial and sealed with a 10mm target septa and 11mm tapones crimp (VWR,
Radnor, PA, USA). The remaining air in the vial was replaced with decafluorobutane
(Fluoromed, Round Rock, TX, USA) via a 20G hypodermic needle (Becton Dickinson, Franklin
Lakes, NJ, USA) and a second needle to vent. The vial was then mixed by a high-speed
amalgamator for 30 s at 4350 CPM (Pelican).

Bacteria Growth and GFP Plasmid Isolation
Luria broth (LB) was prepared by combining NaCl, Tryptone, and Yeast Extract in a
2:2:1 ratio in distilled water. Ampicillin was added right before culture growth began. Using a
sterile pipette tip, a single colony (CMV promoter, ampicillin resistant, cat. no. 11153 from
Addgene, Watertown, MA, USA) was selected from the LB agar plate and dipped into the LB
plus antibiotics mixture and swirled. The culture was covered and allowed to incubate at 37 °C
for 12-18 hours in a shaking incubator. The bacteria were then harvested by centrifugation at
1500g for 5 minutes. The supernatant was removed, and the bacteria were resuspended, lysed,
and neutralized. The supernatant was then transferred to a Thermo Scientific GeneJET Spin
Column and centrifuged for 1 minute and then washed twice, centrifuging for 30-60 s each time.
The column was transferred to a new tube and Elution Buffer was added. The DNA was
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incubated and centrifuged for at 1500g for 2 minutes and the flow-through was collected
(protocol from Thermo Scientific GeneJET Plasmid Miniprep Kit, Thermo Fisher Scientific,
Waltham, MA, USA). Plasmid concentrations were quantified with a NanoDrop 2000C (Thermo
Fisher Scientific).

Lipofectamine-3000 Experiments
Adherent cells were plated in advance and 70-90% confluent at the time of transfection.
Primary suspension cells were isolated prior to transfection. Transfection by Lipofectamine-3000
was completed according to Thermo Fisher Scientific’s supplied protocol (Waltham, MA, USA)
using serum-free medium. GFP plasmid (Addgene, Watertown, MA, USA) dosages ranged
between 250 ng to 1 μg per sample and incubated for 48 hours before analysis. Flow cytometry
analysis was then performed.

Electroporation
A Neon Transfection System and kit was used for electroporation (Thermo Fisher
Scientific). Cells were washed, trypsinized, neutralized, and counted prior to electroporation
process. Cells were centrifuged (1500g for 5 minutes at 4 oC for A549 cells; 580g for 10 minutes
at 4 oC for T-cells), supernatant was aspirated, and cells were resuspended in 100 μL
recommended resuspension buffer (buffer R for A549 cells, buffer T for T-cells) at a density of
1.0 x 107 cells/mL. GFP plasmid (Addgene, Watertown, MA, USA) was added to the cells at a
concentration of 25 ng/μL. Fluorescein was added at 0.1 mg/mL concentration. Electroporation
was conducted following the supplied protocol (Thermo Fisher Scientific). A549 cells and T-cells
were transfected using the following parameters, respectively: 1230V, 30ms, 2 pulses and 500V,
20ms, 1 pulse. The transfected cells were allowed 48 hours for expression after plasmid
transfection and analyzed by flow cytometry. Cells exposed to fluorescein were washed in flow
tubes immediately after electroporation and analyzed by flow cytometry.
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Sonoporation
The cells were collected and washed. The prepared microbubbles were added at
cells:microbubble ratios (199:1, 99:1, 65.7:1, 49:1, 39:1, 19:1) and incubated 1-2 minutes. The
GFP plasmid (1 μg/mL) (Addgene, Watertown, MA, USA) or fluorescein (0.1 mg/mL)
(MilliporeSigma, Burlington, MA, USA) was then added to the samples and passed through a
microfluidic device with a channel diameter of 550 μm at a rate of 30-60 mL/h. Ultrasound was
applied through an integrated transducer at a pressure of 0.1-0.5 MPa. If fluorescein was used,
the samples were kept in fluorescein during the processing for 10 minutes (both control and
sonoporated samples) and washed in flow cytometry tubes directly after. If transfected, the cells
were collected and plated for 24-72 hours to allow time for the GFP plasmid to be internalized
and expressed. The primary T-cells were activated during this time (Dynabeads™ Human TActivator CD3/CD28 for T Cell Expansion and Activation, Thermo Fisher Scientific, Waltham,
MA, USA). Flow cytometry analysis was then performed.

Flow Cytometry Analysis
Transfection and loading efficiency were determined through the detection of GFP
plasmid (Addgene, Watertown, MA, USA) expression or fluorescein uptake via a flow cytometer
(MACSquant, Miltenyi Biotec, Germany; BD FACSCANTO II, BD FACSCalibur, Franklin
Lakes, NJ, USA). Data was analyzed using flow cytometry software (FlowJo, Ashland, OR,
USA). The live cells were gated out by the distribution by forward and side scattering. From
there, the FITC fluorescence intensity was graphed in a histogram (x-axis displaying the
logarithmic fluorescence intensity value and y-axis displaying the cell count) and the mean
fluorescence intensity was obtained by the histogram. These intensities were averaged if the
sample size was larger than one and standard deviations were calculated using Microsoft Excel
2016 (Microsoft, Redmond, WA, USA).
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Statistical Analysis

Statistical comparisons between experimental and control groups were determined using
a Student's t-test, with statistical significance (p < 0.001-0.05) defined under each figure.
Bars represent mean ± standard error.
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III. RESULTS AND DISCUSSION

Fluorescein Loading Studies

Sonoporation Microbubble Dose Study

Cells were sonoporated with fluorescein in the solution to assess the uptake of small
fluorescent molecules.
A range of microbubble volumes were tested. Although the differences seem negligible

Figure 6: Multiple cationic microbubble doses were tested for their sonoporation
loading efficiencies on primary T-Cells. The results were assessed by flow cytometry.
(N=1)

based on the histogram analysis, the 2.5% v/v dose (orange histogram peak) seems to have
the highest fluorescence value (Figure 6). When graphed, the mean fluorescence intensity
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Figure 7: Multiple cationic microbubble doses were tested for their
sonoporation loading efficiencies on primary T-Cells. The results
were assessed by flow cytometry. (N=1)

was shown to be the highest in the 1% and 2.5% microbubble doses (Figure 7). This sample
set had N=1 but this correlates with prior results that were collected from the loading of
fluorescein into red blood cells using sonoporation (Figure 8). This sonoporation was
conducted using a clinical ultrasound probe and water tank but the optimal bubble dose
remains the same. This indicates the importance of the microbubble concentration within
the solution.
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Figure 8: Multiple cationic microbubble doses were tested for their
sonoporation loading efficiencies on red blood cells. The results
were assessed by flow cytometry and the mean fluorescent intensity
(normalized to no treatment control) was graphed. The cells were
treated with a clinical ultrasound probe (Verasonics P4-1
transducer) at 20V, 0.1 ms pulse, 20 mL/hour flow rate in a 200 μm
width microfluidics device channel. (N=4)

Other Transfection Method Assessment of Fluorescein Uptake
Uptake of fluorescein by electroporation was tested alongside the sonoporation data
for comparison. No increase in fluorescence was detected in the first sonoporation
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Figure 9: Primary T-cells were loaded with electroporation (left) and sonoporation (right) and assessed using
flow cytometry. (N=3)
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experiment (Figure 10). Due to the high amount of fluorescence intensity in the nonsonoporated fluorescein control, it was hypothsized that the uptake was saturated by the
nonspecific uptake of the fluorescien. The non-sonoporated fluorescein-only control
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Figure 10: Primary T-Cells were loaded with sonoporation and
assessed using flow cytometry. Fluorescein control procedure
was adjusted to minimize nonspecific uptake of fluorescein.
(N=3)

samples had fluorescein in the solution while the treated samples were being sonoporated.
This was enough time for the cells to nonspecifically take in their maximum amount of
fluorescein. To avoid this issue, experiments were repeated where the non-sonoporated
fluorescein-only controls were left in the fluorescein for less time than in the initial
experiment. The cells only remained in fluorescein for as long as it took to sonoporate one
sample (approximately 11 minutes) and were washed immediately after. A large increase
could then be detected in the loaded sample when compared to the fluorescein-only sample
(Figure 9). When the mean fluorescense was graphed, there was a 3.5-fold increase in the
electroporated sample in comparison to the non-electroporated fluorescein-only control
and a 5-fold increase in the sonoporated sample in comparison to its fluorescein-only
control (Figure 11). These increases were significant with a p-value of less than 0.05. The
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decrease in the fluorescein-only control group’s fluorescence intensity in comparison to
Figure 10 shows that the hypothesized issue of letting the cells rest in fluorescein too long
was accurate. An adjustment to the protocol allowed for a difference in fluorescence
intensity to be measured while using sonoporation as a loading method for fluorescein.
When the electroporation and sonoporation results were compared, the
sonoporation method was more successful at loading the primary T-cells with fluorescein.
The sonoporated sample took in 34% more fluorescein than the electroporated sample.
These results are trending towards signficance with a current p-value of 0.137 (Figure 11).
Additionally, two populations can be detected in the electroporation curve but not in the
sonoporation curve. The two populations indicate a low loading level and a high loading
level. Ultimately, if the same populations are seen with transfection, this could cause an
inconsitent loading of the CAR gene, leading to variability in expression levels of the CAR.
This data indicates that sonoporation may cause more consistent loading which would help
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Figure 11: Primary T-Cells were loaded with electroporation and sonoporation and assessed using
flow cytometry. (*p<0.05) (N=3)
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avoid the unwanted side effects that come from uneven CAR expression, such as cytokine
release syndrome and tumor lysis syndrome. Although electropation has been considered
the more efficient non-viral trasnfection method for primary T-cells, these results suggeset
that sonoporation may actually cause higher, more consistent loading for small molecules
[35]. A higher sample size of this data set would be necessary to conclude significance.

Immune Cell Model Investigation
Additional studies were performed to test loading efficiency in jurkat cells by
means of electroporation to determine if they were an equivalent model for primary Tcells. After electroporation with fluorescein and flow cytometry analysis, there was a
negligible shift measured in the jurkat cells between the fluorescein only control and loaded
samples (Figure 12). In comparison, there was a noticeable shift by the primary T-cells
when comparing the loaded group to the fluorescein-only control group. To further
investigate, the mean fluorescence intensities were graphed (Figure 13). There is a 2-fold
Jurkat Cells

Primary T-Cells

Figure 12: Primary T-Cells and jurkat cells were loaded with electroporation and analyzed by flow cytometry.
(N=1)
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increase in fluorescence intensities between the electroporated primary T-cells and the
fluorescein-only control. The difference is undetectable in the jurkat cells. This not only
aligned with the previously discussed electroporation ex periment, but it also shows that
jurkat cells are not an equivalent model for primary T-cells.
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Figure 13: Primary T-Cells and jurkat cells were loaded with electroporation and analyzed
by flow cytometry. (N=1)

GFP Plasmid Transfection Studies

Sonoporation Microbubble Composition Study

Sonoporation was then tested for its ability to transfect cells with GFP plasmid. Primary Tcells were transfected with GFP plasmid by means of sonoporation using 2.5%
microbubbles % v/v in each sample. At 24 hours, a slight increase in fluorescence could be
distinguished in the cationic microbubble histogram when compared to the control and
neutral microbubble samples (Figure 14). The mean fluorescence intensities of each sample
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Figure 14: Primary T-cells were transfected with GFP plasmid by means of sonoporation and
activated. Flow cytometry was run 24 (left) and 48 hours (right) after treatment. N=1

were graphed. It can again be determined that the most GFP plasmid was expressed (166%
of neutral bubble uptake) when using cationic bubbles for sonoporation and activating the
T-cells for 24 hours before assessment (Figure 15). Although sample sizes were low, these
results are consistent with expected results since the cationic bubbles interact more closely
with the cells which is expected to increase the efficiency of sonoporation.
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Figure 15: Primary T-cells were transfected with GFP plasmid by means
of sonoporation and activated. Flow cytometry was run 24 (left) and 48
hours (right) after treatment and mean fluorescence was graphed. N=1
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Sonoporation T-cell Activation Timepoint Studies
Activation times were explored to understand when the most GFP plasmid was
expressed in the transfected T-cells. The tested time points included 14, 24, 48, and 72
hours. An increase in fluorescence intensity was indistinguishable for the first three time
points (Figure 16-17). It was not until the 48-hour activation time that a shift in the
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fluorescence could be detected (Figure 17).
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Figure 16: Primary T-cells were transfected with GFP plasmid by means of sonoporation and activated. Flow
cytometry was run 14 (left) and 24 hours (right) after treatment. Microbubbles were cationic. N=1
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Figure 17: Primary T-cells were transfected with GFP plasmid by means of sonoporation and activated. Flow cytometry
was run 48 (left) and 72 hours (right) after treatment. Microbubbles were cationic. N=1
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The mean fluorescent intensity results from each timepoint experiment were
normalized to the no treatment controls and combined in Figure 18. From experiment 1, it
can be concluded that the most GFP plasmid was expressed at 24 hours (Figure 18). This
was not replicated, however, when experiment 2 was conducted. The 72-hour timepoint
resulted in the most consistent fluorescence intensity values. Repetitions of the timepoint
study would be necessary for drawing stronger conclusions. As seen in the figure, the
experiments were conducted with low sample sizes. Overall though there does not appear
to be a significant difference at these time points.

Sonoporation Transfection of A549 Cells

Uptake and expression of GFP plasmid by sonoporation transfection methods was
accessed in human lung cancer cells at 48 hours by flow cytometry. No significant
difference was detected between the control and transfected samples (Figure 19). Although
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Figure 18: Primary T-cells were transfected with GFP plasmid by means of sonoporation and
activated. Timepoint data was combined from four different experiments. The results were assessed
by flow cytometry. White number in bar represents number of replicates for each experiment.

33

sonoporation proved its success at loading smaller molecules such as fluorescein, the lack
of success in plasmid transfection suggests that it may not be the best method of loading
larger molecules such as plasmids.
A549 Sonoporation
10%

% FITC+

8%
6%

*

4%
2%
0%
Control

Transfected

Figure 19: Sonoporation transfection was
quantified through %FITC+ cells detected in the
sample by flow cytometry. No significant
difference was detected in the fluorescent levels of
the control vs. transfected samples. (*p<0.05)
(N=2-3)

The lack of success in transfected A549 cells through means of sonoporation
however, could also be explained by the lack of optimization. The ultrasound parameters,
microbubble dose, or plasmid concentration may not have been effective for transfection
of these cells. Sonoporation has proven success as a transfection method in other studies
[36, 37], so future studies with optimized parameters are expected to have higher levels of
transfection. To prove that these cells could be transfected with more standard methods of
transfection, other approaches were tested for comparison with the sonoporation results.

Lipofectamine Transfection

Uptake and expression of GFP plasmid by Lipofectamine 3000 transfection
methods was assessed in primary T-cells and A549 (lung carcinoma) cells at 24 hours by
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flow cytometry (Figure 20). A significant 50-fold increase (p<0.001) in %FITC+ cells was
detected in the transfected cancer cells compared to the non-transfected control group while
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A549 Cells

Figure 20: Lipofectamine 3000 transfection was quantified
through percentage of FITC + cells detected in the sample by
flow cytometry. A 50-fold increase was detected in human lung
cancer cells while no difference was detected in human T-cell
uptake. (*** indicates p<0.0001) (N=3).

no identifiable difference was presented in the T-cells (Figure 20). This indicates that
Lipofectamine3000 may be more successful at transfecting cancer cells when compared to
primary T-cells.

Electroporation Transfection

The mean FITC intensity was evaluated and displayed as histograms for both cell
types (Figure 21). The significant right shift in fluorescence proves the successful
transfection in the human lung cancer cells by means of electroporation. The lack of shift
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in the T-cell histogram further proves the failure to transfect these cells using the described
technique in Zhang, et. al. 2018. This paper loaded 1 μg plasmid while 2.5 μg were loaded
here but the parameters stayed the same. The present study failed to replicate the published
data which reported nearly 60% transfection efficiency with a 3-day post-treatment
incubation [38].

Figure 21: The FITC histograms displayed show the shift in fluorescence between the
control (red) and transfected (blue) samples. The mean intensity of the T-cell
fluorescence did not shift after transfection. These cells were transfected using
electroporation.

Microscopy Analysis

Microscopy Imaging of Electroporation Transfection

Fluorescent microscopy was performed 48 hours after treatment to visualize GFP
plasmid transfection efficiency with electroporation in human lung cancer cells and
primary T-cells (Figure 22). There is a clear uptake and expression of the GFP plasmid by
the cancer cells in the transfected group, shown by the green fluorescent cells detected by
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fluorescent microscopy (Figure 22A-B). The same results were not seen in the primary Tcells (Figure 22C-D). This indicates that after 48 hours, transfection by electroporation was
successful in the cancer cells and sufficient time was given for expression. This further
proves the data discussed previously (Figure 21) that showed the same increase in
fluorescence in the cancer cells.

Microscopy Imaging of Lipofectamine 3000 Transfection

Fluorescent microscopy was performed 24 hours after treatment to visualize GFP
plasmid transfection efficiency with Lipofectamine 3000 in human lung cancer cells and
T-cells (Figure 23). The uptake and expression of the GFP plasmid can be detected in the
human lung cancer cells (Figure 23A-B); however, not in the human T-cells (Figure 23CD). This indicates that after 48 hours, transfection by Lipofectamine 3000 was successful
in the cancer cells and sufficient time was given for expression. This also further proves
that as discussed with Figure 20, Lipofectamine 3000 may not be the best transfection
method for primary T-cells.
The lack of success in transfecting the T-cells with electroporation and
Lipofectamine 3000 further explains how difficult these cells are to transfect. Any success
by sonoporation could show a promising future in using it as a non-viral transfection
method for primary T-cells. Additionally, the differences in fluorescent levels visible in
the microscopy images (Figures 22-23) and wider FITC histogram peaks (Figure 21)
indicates variability in plasmid uptake among individual cells. This is not uncommon for
current methods of transfection. Theoretically, sonoporation using a microfluidics
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approach would introduce a transfection method that would decrease this variability
present in other means of transfection.
A
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Figure 22(A,B): Electroporation transfection conducted in human lung
cancer cells. Control cells (A), GFP plasmid transfected cells (B) dose
=25 ng/µL.
Figure 22(C,D): Electroporation transfection conducted in human Tcells. Control cells (C), GFP plasmid transfected cells (D) dose =25
ng/µL.
Scale bar represents 200 µm.
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Figure 23(A,B): Lipofectamine 3000 transfection conducted in human
lung cancer cells. Control cells (A), GFP plasmid transfected cells (B)
dose =1ng/µL.
Figure 23(C,D): Lipofectamine transfection conducted in human Tcells. Control cells (C), GFP plasmid transfected cells (D) dose =1
ng/µL.
Scale bar represents 200 µm.
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IV. CONCLUSION

Based on the fluorescein studies, sonoporation is a promising method for loading
primary T-cells with small molecules such as fluorescein. We also found that the
incubation time for cells in fluorescein solutions affects the shift in fluorescence intensity
seen on the histograms. Long incubations times can allow cells in the control groups to
passively uptake high amounts of fluorescein which can make it difficult to detect
differences in the treatment groups. It was also determined that jurkat cells are not an
equivalent model for primary T-cells. It can also be concluded that sonoporation is not as
successful at transfecting primary T-cells with larger molecules such as GFP plasmid. This
is most likely due to the size of the loading molecule and also the multiple steps and
pathways involved from plasmid delivery to the production of fluorescent proteins in the
cells.
Optimization of the sonoporation parameters would be necessary to improve the
transfection efficiency of the primary T-cells. These parameters would include
microbubble dose, flow rate, and ultrasound voltage, and possibly introducing pulsed
ultrasound. It would also be beneficial to study a range of plasmid concentrations and
activation timepoints. It is expected that these parameters need to be optimized for each
cell type in order to experience the highest transfection efficiencies. Even though the
current results do not show a large increase in GFP with sonoporation transfection, it is
likely that further research and optimization will lead to improve sonoporation transfection
efficiencies.
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V. RECOMMENDATIONS
Moving forward, more GFP plasmid loading experiments should be conducted to
determine if sonoporation is an effective mode of transfection for T-cells. A range of
ultrasound parameters (pressure and pulse iteration) in addition to flow rates and
microbubble concentrations should be tested. Additionally, a range of GFP plasmid
concentrations and activation timepoints should be studied. These experiments should be
repeated for both technical replicates and experiment replicates to prove consistency in the
results. While these are being run, the donor should remain the same. Once consistency is
proven, transfection by sonoporation should be tested in a range of T-cell donors to make
sure the results can be repeated in primary T-cells from different sources.
Once sonoporation and the loading of GFP plasmid is improved, the next step will
be loading CARs into the primary T-cells and testing for their presence and ability to
express the receptor. The specific insertion of the CAR into the genome can be improved
by the addition of CRISPR-Cas9 into the transfection process. Ideally while this project
advances, not only will sonoporation be established as the best method of non-viral
transfection, but the expression consistency will be improved with the use of CRISPRCas9 to decrease unwanted symptoms of the CAR-T treatment and improve outcomes in
patients.

40

REFERENCES
1.

Pui, C.H. and W.E. Evans, Treatment of acute lymphoblastic leukemia. N Engl J
Med, 2006. 354(2): p. 166-78.

2.

Pui, C.H. Acute Lymphoblastic Leukemia. Encyclopedia of Cancer 2017; 2011:[

3.

Hunger, S.P., et al., Improved survival for children and adolescents with acute
lymphoblastic leukemia between 1990 and 2005: a report from the children's
oncology group. J Clin Oncol, 2012. 30(14): p. 1663-9.

4.

Childhood Acute Lymphoblastic Leukemia Treatment. 2018 [cited 2019 07]; 13].
Available from: www.cancer.gov/types/leukemia/patient/child-all-treatment-pdq.

5.

Zelent, A., M. Greaves, and T. Enver, Role of the TEL-AML1 fusion gene in the
molecular pathogenesis of childhood acute lymphoblastic leukaemia. Oncogene,
2004. 23(24): p. 4275-83.

6.

Arruga, F., et al., Functional impact of NOTCH1 mutations in chronic
lymphocytic leukemia. Leukemia, 2014. 28(5): p. 1060-70.

7.

Imatinib mesylate. PubChem [cited 2019 07].

8.

Press Announcements - FDA Approval Brings First Gene Therapy to the United
States. Available from:
www.fda.gov/newsevents/newsroom/pressannouncements/ucm574058.htm.

9.

Niederhuber, J.E., Abeloff's Clinical Oncology: Fifth Edition. 2013: Elsevier, Inc.

10.

Jain, N., Acute Lymphoblastic Leukemia in Adults. Hematology: Basic Principles
and Practice, 2013. 6.

11.

Harr, J., Civil Action. 1996: Vintage Books.

41

12.

Lange, B.J., et al., Double-delayed intensification improves event-free survival for
children with intermediate-risk acute lymphoblastic leukemia: a report from the
Children's Cancer Group. Blood, 2002. 99(3): p. 825-33.

13.

Gragert, L., et al., HLA match likelihoods for hematopoietic stem-cell grafts in the
U.S. registry. N Engl J Med, 2014. 371(4): p. 339-48.

14.

Possible Side Effects of Mercaptopurine PO, Methotrexate PO. 2014; Available
from:
https://ctep.cancer.gov/protocolDevelopment/sideeffects/regimes/SideEffectsMercapt-Methotrex-Pred-Vincrist.doc.

15.

Grupp, S.A., et al., Chimeric antigen receptor-modified T cells for acute lymphoid
leukemia. N Engl J Med, 2013. 368(16): p. 1509-1518.

16.

Maude, S.L., et al., Chimeric antigen receptor T cells for sustained remissions in
leukemia. N Engl J Med, 2014. 371(16): p. 1507-17.

17.

Maude, S.L., et al., CD19-targeted chimeric antigen receptor T-cell therapy for
acute lymphoblastic leukemia. Blood, 2015. 125(26): p. 4017-23.

18.

Fesnak, A.D., C.H. June, and B.L. Levine, Engineered T cells: the promise and
challenges of cancer immunotherapy. Nat Rev Cancer, 2016. 16(9): p. 566-81.

19.

Brentjens, R.J., et al., CD19-targeted T cells rapidly induce molecular remissions
in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl
Med, 2013. 5(177): p. 177ra38.

20.

Bonifant, C.L., et al., Toxicity and management in CAR T-cell therapy. Mol Ther
Oncolytics, 2016. 3: p. 16011.

42

21.

Davila, M.L., et al., Efficacy and toxicity management of 19-28z CAR T cell
therapy in B cell acute lymphoblastic leukemia. Sci Transl Med, 2014. 6(224): p.
224ra25.

22.

Howard, S.C., D.P. Jones, and C.H. Pui, The tumor lysis syndrome. N Engl J Med,
2011. 364(19): p. 1844-54.

23.

Douglas, K.L., Toward development of artificial viruses for gene therapy: a
comparative evaluation of viral and non-viral transfection. Biotechnol Prog,
2008. 24(4): p. 871-83.

24.

Rothe, M., A. Schambach, and L. Biasco, Safety of gene therapy: new insights to
a puzzling case. Curr Gene Ther, 2014. 14(6): p. 429-36.

25.

DeBruin, K.A. and W. Krassowska, Modeling electroporation in a single cell. I.
Effects Of field strength and rest potential. Biophys J, 1999. 77(3): p. 1213-24.

26.

Potter, H. and R. Heller, Transfection by Electroporation. Curr Protoc Mol Biol,
2018. 121: p. 9 3 1-9 3 13.

27.

Zhao, D., et al., A Flow-Through Cell Electroporation Device for Rapidly and
Efficiently Transfecting Massive Amounts of Cells in vitro and ex vivo. Sci Rep,
2016. 6: p. 18469.

28.

van Wamel, A., et al., Vibrating microbubbles poking individual cells: drug
transfer into cells via sonoporation. J Control Release, 2006. 112(2): p. 149-55.

29.

Fan, Z., R.E. Kumon, and C.X. Deng, Mechanisms of microbubble-facilitated
sonoporation for drug and gene delivery. Ther Deliv, 2014. 5(4): p. 467-86.

43

30.

Kopechek, J.A., et al., Ultrasound Targeted Microbubble Destruction-Mediated
Delivery of a Transcription Factor Decoy Inhibits STAT3 Signaling and Tumor
Growth. Theranostics, 2015. 5(12): p. 1378-87.

31.

Hu, Y., J.M. Wan, and A.C. Yu, Membrane perforation and recovery dynamics in
microbubble-mediated sonoporation. Ultrasound Med Biol, 2013. 39(12): p.
2393-405.

32.

Almasbak, H., T. Aarvak, and M.C. Vemuri, CAR T Cell Therapy: A Game
Changer in Cancer Treatment. J Immunol Res, 2016. 2016: p. 5474602.

33.

Ramachandran, H., et al., Optimal thawing of cryopreserved peripheral blood
mononuclear cells for use in high-throughput human immune monitoring studies.
Cells, 2012. 1(3): p. 313-24.

34.

Sadeghi, A., et al., Rapid expansion of T cells: Effects of culture and
cryopreservation and importance of short-term cell recovery. Acta Oncol, 2013.
52(5): p. 978-86.

35.

Riedl, S.A.B., Non-Viral Transfection of Human T Lymphocytes. Processes, 2018.

36.

Bao, S., B.D. Thrall, and D.L. Miller, Transfection of a reporter plasmid into
cultured cells by sonoporation in vitro. Ultrasound Med Biol, 1997. 23(6): p. 9539.

37.

Tlaxca, J.L., et al., Analysis of in vitro transfection by sonoporation using cationic
and neutral microbubbles. Ultrasound Med Biol, 2010. 36(11): p. 1907-18.

38.

Zhang, Z., et al., Optimized DNA electroporation for primary human T cell
engineering. BMC Biotechnol, 2018. 18(1): p. 4.

44

VITA
Emily Murphy received her Bachelor of Science in Bioengineering from the
University of Louisville in 2018. In 2016, she began her co-op career under Dr. Jonathan
Kopechek and Dr. Tariq Malik, located primarily in the Clinical and Translational
Research Building. Her focus was in a cancer-targeting nanoemulsions project utilizing the
aptamer AS1411. Her following co-op rotations were primarily under Dr. Jonathan
Kopechek and was in his Theranostics Ultrasound Laboratory. Her project involved using
an ultrasonic flow system for long-term preservation of red blood cells with a collaboration
with Dr. Michael Menze in the Biology Department at the University of Louisville. Her
focus then shifted to transfection methods and the use of sonoporation as a non-viral
transfection method for CAR-T therapy and began the collaboration with Dr. Kavitha
Yaddanapudi. Currently, Emily is finishing her Master of Engineering degree in
Bioengineering at the University of Louisville under Dr. Jonathan Kopechek and expects
to graduate at the beginning of August 2019. She will then be relocating to the
Baltimore/Washington DC area to continue her research career as a Biologist I in a
respiratory toxicology laboratory under Dr. Holger Behrsing.

45

